Risk information from 2012
Here you will find BfArM risk information from the current year.
Risk information from past years is found under the appropriate navigation points.
RSS-Feed available for actual risk information
| Date | Title | Link |
|---|---|---|
| 2012.02.02 |
Mircera® (methoxy polyethylene glycol-epoetin beta): Possible shortages: Note on switching to alternative treatments An information letter with treatment recommendations has been circulated to treating physicians and pharmacies concerned. |
to article |
| 2012.01.27 |
Dear Doctor Letter (Rote-Hand-Brief) on Gilenya® (fingolimod): Increased cardiovascular monitoring at the beginning of treatment Important additional recommendations regarding a more intense monitoring of cardiovascular functions at the beginning of treatment with Gilenya® (fingolimod) in patients with relapsing-remitting multiple sclerosis. |
to article |
| 2012.01.16 |
Dear Doctor Letter (Rote-Hand-Brief) on Velcade® (bortezomib): Intravenous injection is the only correct route of administration The only licensed route of administration of Velcade® (1 mg, 3.5 mg, powder for solution for injection) is via intravenous injection. Velcade® must not be administered in any other manner. |
to article |